Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
Zacks News
What's in Store for Boston Scientific's (BSX) Q4 Earnings?
by Zacks Equity Research
On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.
Boston Scientific (BSX) Hit by Procedure Deferrals Amid COVID
by Zacks Equity Research
Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.
4 Internet of Medical Things (IoMT) Stocks to Buy for 2022
by Riya Anand
Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.
The Zacks Analyst Blog Highlights: JPMorgan, Walmart, PayPal, Equinix and Boston Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Walmart, PayPal, Equinix and Boston Scientific
Top Analyst Reports for JPMorgan, Walmart & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Walmart Inc. (WMT), and PayPal Holdings, Inc. (PYPL).
Top Analyst Reports for JPMorgan, Walmart & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Walmart Inc. (WMT), and PayPal Holdings, Inc. (PYPL).
Boston Scientific (BSX) New Buyouts Aid Amid COVID Resurgence
by Zacks Equity Research
Boston Scientific's (BSX) new acquisitions like Preventice, Farapulse and Lumenis Surgical, which closed in March, August and September of 2021, respectively, are contributing to its inorganic growth.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.
The Zacks Analyst Blog Highlights: Alibaba, Abbott Laboratories, T-Mobile, Anheuser-Busch and Boston Scientific Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Abbott Laboratories, T-Mobile, Anheuser-Busch and Boston Scientific Corp
Top Analyst Reports for Alibaba, Abbott & T-Mobile US
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Abbott Laboratories (ABT), and T-Mobile US, Inc. (TMUS).
QIPT vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
QIPT vs. BSX: Which Stock Is the Better Value Option?
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.
Boston Scientific (BSX) Q3 Earnings Beat Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.50% and -1.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.
Boston Scientific (BSX) Product Launches to Drive Q3 Earnings
by Zacks Equity Research
Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable
by Zacks Equity Research
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
Boston Scientific (BSX) Reports Data Backing Eluvia Stent
by Zacks Equity Research
The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
by Debanjana Dey
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) owing to new product flow and strong market share gain across the company's businesses.
NVST or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes
by Zacks Equity Research
Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.